Vittal Vasista - 19 Mar 2024 Form 4 Insider Report for REGENXBIO Inc. (RGNX)

Role
Chief Financial Officer
Signature
/s/ Patrick J. Christmas as attorney-in-fact
Issuer symbol
RGNX
Transactions as of
19 Mar 2024
Net transactions value
+$75,354
Form type
4
Filing time
21 Mar 2024, 17:20:42 UTC
Previous filing
04 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RGNX Common Stock Options Exercise $75,354 +20,041 +8.8% $3.76 246,534 19 Mar 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RGNX Employee Stock Option (Right to Buy) Options Exercise $0 -20,041 -100% $0.000000* 0 19 Mar 2024 Common Stock 20,041 $3.76 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The previously granted option, representing a right to purchase a total of 30,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter.